Pricing

Five things for pharma marketers to know: Thursday, May 12, 2016

Five things for pharma marketers to know: Thursday, May 12, 2016

By

Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart

Reframing the Debate: Why Drug Spending Can Lower Costs

Reframing the Debate: Why Drug Spending Can Lower Costs

Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off

Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

By

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

Five things for pharma marketers to know: Wednesday, April 27, 2016

Five things for pharma marketers to know: Wednesday, April 27, 2016

By

Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula

Zika Crisis Stresses Need for Pharma Industry

Zika Crisis Stresses Need for Pharma Industry

By

When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.

Five things for pharma marketers to know: Thursday, April 14, 2016

Five things for pharma marketers to know: Thursday, April 14, 2016

By

Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license

Five things for pharma marketers to know: Tuesday, April 12, 2016

Five things for pharma marketers to know: Tuesday, April 12, 2016

By

California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

By

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, April 1, 2016

Five things for pharma marketers to know: Friday, April 1, 2016

By

GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance

Another physician group raises concerns about DTC

Another physician group raises concerns about DTC

By

The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.

Five things for pharma marketers to know: Monday, March 21, 2016

Five things for pharma marketers to know: Monday, March 21, 2016

By

Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development

Five things for pharma marketers to know: Friday, March 18, 2016

Five things for pharma marketers to know: Friday, March 18, 2016

By

OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader

Shkreli's Actions Result in Broader Industry Upshot

Shkreli's Actions Result in Broader Industry Upshot

By

Exactly how does the erosion of public trust in the goodwill of the pharma industry impact the work being done to raise awareness and also market medicines? It's hard to tell, so far.

Finding a Better Strategy for Pricing Drugs

Finding a Better Strategy for Pricing Drugs

We need to consider that not every expenditure is beneficial to patients: perhaps that Super Bowl commercial or that sales meeting in Maui may not be in their best interest.

Pricing debate changes perception of patient assistance programs

Pricing debate changes perception of patient assistance programs

By

Providing financial assistance to patients has become a common refrain in drugmakers' defense of high-priced drugs.

Five things for pharma marketers to know: Friday, February 12, 2016

Five things for pharma marketers to know: Friday, February 12, 2016

By

Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar

House Oversight committee upbraids Turing, Valeant execs

House Oversight committee upbraids Turing, Valeant execs

By

A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."

Five things for pharma marketers to know: Thursday, February 4, 2016

Five things for pharma marketers to know: Thursday, February 4, 2016

By

Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

4 Ways to Create a Sustainable Pricing Model

4 Ways to Create a Sustainable Pricing Model

The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.

Medicines360 CEO battles for IUD access

Medicines360 CEO battles for IUD access

By

Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.

Five things for pharma marketers to know: Wednesday, January 20, 2016

Five things for pharma marketers to know: Wednesday, January 20, 2016

By

Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales

Five things for pharma marketers to know: Tuesday, January 19, 2016

Five things for pharma marketers to know: Tuesday, January 19, 2016

By

Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business

Five things for pharma marketers to know: Thursday, January 14, 2016

Five things for pharma marketers to know: Thursday, January 14, 2016

By

Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients

The year's top pharma marketing controversies

The year's top pharma marketing controversies

By

Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.

DCI Group aids Turing amid drug price, Shkreli controversies

DCI Group aids Turing amid drug price, Shkreli controversies

By

The firm began working with the pharma company before outrage over its drug pricing but has more recently supported the client after former CEO Martin Shkreli was arrested.

New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

By

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

Five things for pharma marketers to know: Monday, December 21, 2015

Five things for pharma marketers to know: Monday, December 21, 2015

By

Shkreli resigns from Turing; Keytruda approved as first-line melanoma treatment; drugmakers seek to fend off California pricing ballot initiative

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

By

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Monday, December 14, 2015

Five things for pharma marketers to know: Monday, December 14, 2015

By

Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug

OPINION

Email Newsletters